About City of Hope

City of Hope is an independent research and treatment center for diabetes, cancer and other life-threatening diseases. City of Hope is the home of seminal National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) programs, such as the Human Islet Research Network (HIRN) and the Integrated Islet Distribution Program (IIDP), that lead the field of diabetes in diabetes research and translational potential. Designated as one of only 51 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world.

City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of immunotherapies and clinical islet transplantation for diabetes, bone marrow transplantation and numerous breakthrough cancer drugs, all based on technology developed at the institution.

City of Hope’s Commitment to Diabetes Research

Bringing together the best in bench-to bedside research, City of Hope’s Arthur Riggs Diabetes & Metabolism Research Institute (AR-DMRI) is one of the world’s most comprehensive diabetes research programs.

City of Hope has a long and impressive history of groundbreaking discoveries in the field of diabetes spanning more than five decades of intense investigation since Rachmiel Levine, M.D., who discovered the role of insulin in glucose transport, launched diabetes research at City of Hope in the 1970s.

City of Hope's Arthur Riggs Diabetes & Metabolism Research Institute is named for Arthur D. Riggs, Ph.D., another pioneer in the field famous for his work on synthesizing the first man-made gene and using synthetic genes to produce human insulin. This first practical source of human insulin has become the standard of care for diabetes worldwide. The AR-DMRI is headed by Debbie Thurmond, Ph.D., a renowned research scientist, professor and founding chair of the Department of Molecular & Cellular Endocrinology.

City of Hope’s commitment to Diversity, Equity and Inclusion

• We believe diversity is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all of our communities.
• Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds and experiences to our work -- and that our teams align with the people we serve in order to build trust and understanding.
• We are dedicated to fostering a community that embraces diversity  – in ideas, backgrounds and perspectives; this is reflected in our work and represented in our people.
• We are proud to be an Equal Opportunity Employer.

In the News:

NEWS RELEASES

RESEARCHERS IDENTIFY NEW TARGET FOR POTENTIAL TYPE 1 DIABETES TREATMENT

CITY OF HOPE AIMS TO CURE TYPE 1 DIABETES IN SIX YEARS

THE WANEK FAMILY PROJECT TO CURE TYPE 1 DIABETES: 18 MONTHS LATER

ISLET CELL TRANSPLANT HELPS DIABETES PATIENT PUT THREE DECADES OF COMPLICATIONS BEHIND HIM

FOR THIS DIABETES RESEARCHER, THE MISSION IS PERSONAL

CANCER AND DIABETES: MORE CONNECTIONS THAN YOU THINK

THE ENDURING LEGACY OF CITY OF HOPE’S JAPANESE-AMERICAN SCIENTISTS

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE AWARDS CITY OF HOPE $5.74 MILLION FOR SEVERE SICKLE CELL DISEASE CLINICAL TRIAL

REELING IN THE PAST: RESEARCH GIVES NEW LIFE TO OLD MODEL OF DNA LOOPING

NEW CLUES COULD POINT TO BETTER TREATMENTS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD)

BART ROEP, PH.D., HAS TYPE 1 DIABETES CURE IN HIS SIGHTS

STEM CELL TRANSPLANTS LEAD TO CURE FOR SOME TYPE 1 DIABETES PATIENTSFOR DIABETES PATIENTS, ISLET IMPLANTS IN SKIN SHOW PROMISE

INSULIN-FREE DIABETES PATIENT SHARES LIFE-CHANGING TREATMENT ON “THE DOCTORS”

Position Summary

The department of Molecular and Cellular Endocrinology at Beckman Research Institute of City of Hope has an opening for an Assistant Research Professor.

Basic education, experience and skills required for consideration:

• PhD degree in biological sciences or related field and have a demonstrable record of accomplishments, peer-reviewed publications and record of extramural funding at any level preferred, but not required. 
• Islet biology experience preferred.

Preferred education experience and skills:

• Postdoctoral Training
• Experience in primary mammalian cell, clonal beta cell cultures and cell-based assays including beta-cell models. Experience working with primary pancreatic human islets a plus. Experience with transfection and transduction techniques preferred.
• Skilled in confocal microscopy, flow Cytometry, Microscopy, IHC, ELISA preferred
• Proficient in molecular biology techniques, such as PCR, RT-PCR,
• Track record of challenging oneself to enhance scientific abilities
• Proven and successful track record as a team-player and collaborator in the working environments
• Highly organized and detail oriented with a passion to deliver quality results
• Excellent verbal and written communication skills, with experience translating technical concepts into user-friendly documentation
• Extensive experience in animal models of diabetes and genetically manipulated animal models.
• Identify new technology platforms to gain knowledge in diabetes research
• Proficiency to lead a group of junior scientists and accomplish the projects successfully with a keen sense of urgency.
• Ability to work with IACUC protocols preferred.

Additional Information:

As a condition of employment, City of Hope requires staff to comply with all state and federal vaccination mandates.

City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer.  All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability.

#PD

#LI-MA